ALNYLAM PHARMACEUTICALS Reports Q2 2023 Earnings Results on June 30, 2023
August 24, 2023
🌥️Earnings Overview
On June 30, 2023, ALNYLAM PHARMACEUTICALS ($NASDAQ:ALNY) announced its financial results for the second quarter of 2023. This year, total revenue was reported at USD 318.8 million, a gain of 41.8% compared to the same quarter of the prior year. Net income, however, decreased slightly from -277.4 million to -276.0 million when compared to the same period in 2022.
Stock Price
On Thursday, June 30th, 2023 ALNYLAM PHARMACEUTICALS reported its earnings results for the second quarter of 2023. The company’s stock opened at $182.1 and closed at $190.1, an increase of 1.7% from its last closing price of $187.0. The company attributed this strong performance to its focus on investing in new products and services while maintaining a disciplined approach to its R&D expenditures. The company’s management team believes that its investments in new products and services will provide a competitive edge that will help them succeed in the long-term.
Furthermore, they remain committed to delivering a strong financial performance by streamlining operations and focusing on efficiency and cost control. This, coupled with their aggressive innovation strategy should help them stay ahead of the competition in the long-term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Alnylam Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 1.24k | -1.06k | -76.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Alnylam Pharmaceuticals. More…
| Operations | Investing | Financing |
| -472.72 | 89.05 | 460.23 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Alnylam Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.4k | 3.81k | -3.28 |
Key Ratios Snapshot
Some of the financial key ratios for Alnylam Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 53.0% | – | -75.1% |
| FCF Margin | ROE | ROA |
| -43.7% | 174.1% | -17.1% |
Analysis
GoodWhale performed an analysis of ALNYLAM PHARMACEUTICALS‘s wellbeing. Our Star Chart showed that the company was strong in growth, medium in asset and weak in dividend and profitability. Based on this evaluation, ALNYLAM PHARMACEUTICALS was classified as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. As such, we believe that investors interested in taking on a higher risk would be more likely to invest in ALNYLAM PHARMACEUTICALS. However, its health score of 2/10 with regard to cashflows and debt is not particularly good. This means that the company is less likely to be able to pay off debt and fund future operations. Therefore, investors should be aware of the potential risks before investing in the company. More…
Peers
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam’s competitors include Regeneron Pharmaceuticals Inc, Intellia Therapeutics Inc, and Novartis AG.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
As of 2022, Regeneron Pharmaceuticals Inc has a market cap of 79.02B and a Return on Equity of 19.7%. The company is a biotech company that focuses on the discovery, development, and commercialization of medicines for the treatment of serious medical conditions.
– Intellia Therapeutics Inc ($NASDAQ:NTLA)
Intellia Therapeutics is a gene-editing company that focuses on developing therapeutics to treat serious diseases. The company has a market cap of $3.96 billion as of 2022 and a return on equity of -26.91%. Intellia’s gene-editing technology is based on CRISPR-Cas9, which is a naturally occurring bacterial system that can be used to target and edit specific genes. The company’s pipelines include programs for sickle cell disease, beta thalassemia, Huntington’s disease, and transthyretin amyloidosis.
– Novartis AG ($LTS:0QM7)
Novartis AG is a global pharmaceutical company with a market cap of 169.13B as of 2022. It has a Return on Equity of 24.65%. The company focuses on the discovery, development, and commercialization of healthcare products. Novartis’s products include over-the-counter and prescription drugs, vaccines, and diagnostic tools. The company has operations in over 140 countries and its products are sold in 180 countries.
Summary
ALNYLAM PHARMACEUTICALS reported its earnings results for the second quarter of 2023, achieving a total revenue of USD 318.8 million, a 41.8% increase from the same quarter of the previous year. Net income was reported at USD -276.0 million, down slightly from the -277.4 million reported in the prior year. For investors, this could indicate an improvement in the company’s financial performance year-over-year, while further analysis is needed to make a conclusive investment decision. It is also important to keep an eye on emerging trends in the industry and any potential risks that could affect ALNYLAM’s future performance.
Related Posts
Recent Posts
